drugset
drugset / Trial / NCT03082833

Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy

NCT03082833 ↗

Phase 2 Terminated 1 enrolled Samsung Medical Center
NaSingle-groupOpen-labelTreatment

Summary

Phase II trial of AZD2014 in TSC1/2 mutated or TSC1/2 null GC patients as second-line chemotherapy

Timeline

Start
2017-02-01
Primary completion
2018-11-16
Completion
2018-11-16

Drugs

EvaluationDrugModalityDoseRoute
Subject Vistusertib Small molecule 50 mg —

Indications

gastric cancer